European Journal of Clinical Pharmacology

, Volume 30, Issue 3, pp 295–298 | Cite as

Cefodizime penetration into skin suction blister fluid following a single intravenous dose

  • M. Schäfer-Korting
  • H. C. Korting
  • L. Maaß
  • N. Klesel
  • H.-G. Grigoleit
  • E. Mutschler
Originals

Summary

Cefodizime pharmacokinetics was investigated, evaluating drug concentrations in serum, skin suction blister fluid (SBF), saliva and urine in six healthy male subjects who were administered a 1-g dose intravenously. Serum levels in five subjects can be described according to a two-compartment open model; terminal half-life is 181±14 min. Volume of distribution (V) amounts to 15.3±1.61, serum clearance to 59±6 ml/min, renal clearance to 33±3 ml/min. Of the administered dose, 54% is renally excreted unchanged within 27 h. Unbound drug fraction in serum is 19.0% and in SBF 38.4%. Thus renal clearance of free cefodizime amounts to 172 ml/min, Vdss to 68.91 (free drug). Whereas cefodizime has not been detected in saliva samples, SBF concentration 3–9 h post administration parallel serum levels, amounting to 40% of the respective serum concentration. At 9 h, unbound cefodizime concentrations in SBF amount to 1.4±0.4 µg/ml, this value being well above the MIC90% values of many clinically relevant bacteria.

Key words

cefodizime skin suction blister fluid pharmacokinetics protein binding healthy subjects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Limbert M, Klesel N, Seeger K, Seibert G, Winkler I, Schrinner E (1984) Cefodizime, an aminothiazolylcephalosporin. I. In vitro activity. J Antibiot 37: 892–900Google Scholar
  2. 2.
    Klesel N, Limbert M, Seeger K, Seibert G, Winkler I, Schrinner E (1984) Cefodizime, an aminothiazolylcephalosporin. II. Comparative studies on the pharmacokinetic behaviour in laboratory animals. J Antibiot 37: 901–909Google Scholar
  3. 3.
    Kiistala U (1968) Suction blister device for separation of viable dermis from epidermis. J Invest Dermatol 50: 129–137Google Scholar
  4. 4.
    Vermeer BJ, Reman FC, van Gent CM (1979) The determination of lipids and proteins in suction-blister fluid. J Invest Dermatol 73: 303–305Google Scholar
  5. 5.
    Herfst MJ, van Rees H (1978) Suction blister fluid as a model for interstitial fluid in rats. Arch Dermatol Res 263: 325–334Google Scholar
  6. 6.
    Schäfer-Korting M, Grimm HW, Mutschler E (1985) Morphologische, biochemische und pharmakokinetische Untersuchungen an Saugblasen in Abhängigkeit von der Art und dem Zeitpunkt ihrer Entstehung. Arch Pharm (Weinheim) 318: 711–720Google Scholar
  7. 7.
    Mucklow JC, Bending MR, Kahn GC, Dollery CT (1978) Drug concentrations in saliva. Clin Pharmacol Ther 24: 563–570Google Scholar
  8. 8.
    Schäfer-Korting M, Korting HC, Dorn M, Mutschler E (1984) Ketoconazole concentrations in human skin blister fluid and plasma. Int J Clin Pharmacol Ther Toxicol 22: 371–374Google Scholar
  9. 9.
    McNamara PJ, Gibaldi M, Stoeckel K (1983) Fraction unbound in interstitial fluid. J Pharm Sci 72: 834–836Google Scholar
  10. 10.
    Schäfer-Korting M, Korting HC, Mutschler E (1985) Human plasma and skin blister fluid levels of griseofulvin after its repeated administration. Eur J Clin Pharmacol 29: 351–354Google Scholar
  11. 11.
    Hattingberg HM von, Brockmeier D, Kreuter G (1977) A rotating iterative procedure (RIP) for estimating hybrid constants in multicompartment analysis on desk computers. Eur J Clin Pharmacol 11: 381–388Google Scholar
  12. 12.
    Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Hamilton, IllinoisGoogle Scholar
  13. 13.
    Cunha BA, Ristuccia AM (1982) Third generation cephalosporins. Med Clin North Am 66: 283–291Google Scholar
  14. 14.
    Flurlanut M, Montanari G, Padrini R, Meinradi G, Tamassia V, Bruno R (1983) Pharmacokinetics of ceftizoxime in healthy adult volunteers. Drugs Exp Clin Res 9: 657–659Google Scholar
  15. 15.
    Granneman GR, Senello LT, Steinberg FJ, Sonders RC (1982) Intramuscular and intravenous pharmacokinetics of cefmenoxime, a new broad-spectrum cephalosporin, in healthy subjects. Antimicrob Agents Chemother 21: 141–145Google Scholar
  16. 16.
    Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ Jr (1982) Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults. Antimicrob Agents Chemother 22: 816–823Google Scholar
  17. 17.
    Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler WH (1981) Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther 29: 650–657Google Scholar
  18. 18.
    Korting HC (1984) Plasma and skin blister fluid levels of cefotiam and cefmenoxime after a single intramuscular application of 1 g in gonorrhea. Chemother 30: 277–282Google Scholar
  19. 19.
    Korting HC, Schäfer-Korting M, Haag R, Mutschler E (1984) Plasma, cantharides blister fluid, and suction blister fluid levels of ceftizoxime after single intramuscular application for gonorrhea. Int J Clin Pharmacol Ther Toxicol 22: 218–220Google Scholar
  20. 20.
    Bergan T, Kalager T, Hellum KB, Solberg CO (1982) Penetration of cefotaxime and desacetylcefotaxime into skin blister fluid. J Antimicrob Chemother 10: 193–196Google Scholar
  21. 21.
    Danhof M, Breimer DD (1978) Therapeutic drug monitoring in saliva. Clin Pharmacokinet 3: 39–57Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • M. Schäfer-Korting
    • 1
  • H. C. Korting
    • 2
  • L. Maaß
    • 3
  • N. Klesel
    • 4
  • H.-G. Grigoleit
    • 3
  • E. Mutschler
    • 1
  1. 1.Pharmakologisches Institut für Naturwissenschaftler der Johann Wolfgang Goethe-UniversitätFrankfurt am MainFederal Republic of Germany
  2. 2.Dermatologische Klinik und Poliklinik der Ludwig-Maximilians-UniversitätMünchenFederal Republic of Germany
  3. 3.Klinische Forschung, Abteilung für Klinische PharmakologieHoechst AGFrankfurt am MainFederal Republic of Germany
  4. 4.Pharma Forschung, Abteilung für ChemotherapieHoechst AGFrankfurt am MainFederal Republic of Germany

Personalised recommendations